Pharma Capital
EPIC: PAR
Market: ASX
52-week High/Low: A$0.72 / A$0.23
Sector: Pharma & Biotech
Market Cap: A$39.75M

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.

.

Paradigm Biopharmaceuticals Ltd

www.paradigmbiopharma.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Snapshot

Paradigm Biopharmaceuticals (ASX:PAR) is listed on the ASX in August 2015. Our focus is on repurposing pentosan polysulphate sodium (PPS), an FDA approved drug that has a long track record of treating inflammation, having been used narrowly to treat bladder inflammation (interstitial cystitis) and for preventing DVT. We focus on the application of PPS in diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.

We have a robust programme of clinical development, with our major clinical investigations currently focussing on the treatment of orthopaedic conditions, respiratory conditions, and the debilitating arthritis associated with arthritogenic alphaviruses (Ross River virus and chikungunya).

By working closely with the proprietary manufacturer of PPS, Paradigm Biopharma can leverage substantial knowledge and expertise available from earlier regulatory filings and accumulated toxicology safety data. With this foundation, we minimise our risk profile, and are able to accelerate the drug development cycle at significantly reduced costs.

Paul Rennie (Managing Director)

Paul Rennie, Managing Director (BSc, MBM, Grad Dip Commercial Law, MSTC), has extensive sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. Paul’s experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their director of business development.

Paul also led the commercialisation of Recaldent® a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took this R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in a number of positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. Paul founded Paradigm in early 2015.


Graeme Kaufman (Non-Executive Chairman)

Graeme Kaufman, Non-Executive Chairman (BSc, MBA), has wide ranging experience across the biotechnology sector, spanning scientific, commercial and financial areas. His experience with CSL Limited, Australia’s largest biopharmaceutical company included responsibility for their global manufacturing operations facilities, and the management of an independent business division operating in the high technology medical device market.

As CSL’s General Manager Finance, Mr Kaufman had global responsibility for finance, strategy development, human resources and information technology. Mr Kaufman has also served as an executive director of ASX-listed Circadian Technologies (now Opthea) and a non-executive director of Amrad Corporation, and held the role of Executive Vice President Corporate Finance with Mesoblast Limited until 2013. He is currently Chairman of Bionomics Limited and IDT Australia Limited, and non-executive director of Cellmid Limited.

Paradigm Biopharmaceuticals Ltd Timeline

View All

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.